Jazirehi AR - Search Results

1

Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.

Jazirehi AR. Jazirehi AR. Int J Mol Sci. 2021 Oct 29;22(21):11726. doi: 10.3390/ijms222111726. Int J Mol Sci. 2021. PMID: 34769156 Free PMC article. Review.

2

T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy.

Quatromoni JG, Wang Y, Vo DD, Morris LF, Jazirehi AR, McBride W, Chatila T, Koya RC, Economou JS. Quatromoni JG, et al. Among authors: jazirehi ar. J Transl Med. 2012 Jun 19;10:127. doi: 10.1186/1479-5876-10-127. J Transl Med. 2012. PMID: 22713761 Free PMC article.

3

Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Jazirehi AR, Economou JS. Jazirehi AR, et al. Mol Cancer Ther. 2012 Jun;11(6):1332-41. doi: 10.1158/1535-7163.MCT-11-0814. Epub 2012 Apr 24. Mol Cancer Ther. 2012. PMID: 22532603 Free PMC article. Retracted.

4

Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.

Jazirehi AR, Kurdistani SK, Economou JS. Jazirehi AR, et al. J Immunol. 2014 Apr 15;192(8):3981-9. doi: 10.4049/jimmunol.1302532. Epub 2014 Mar 17. J Immunol. 2014. PMID: 24639349 Free PMC article.

5

Pioneer factor interactions and unmethylated CpG dinucleotides mark silent tissue-specific enhancers in embryonic stem cells.

Xu J, Pope SD, Jazirehi AR, Attema JL, Papathanasiou P, Watts JA, Zaret KS, Weissman IL, Smale ST. Xu J, et al. Among authors: jazirehi ar. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12377-82. doi: 10.1073/pnas.0704579104. Epub 2007 Jul 18. Proc Natl Acad Sci U S A. 2007. PMID: 17640912 Free PMC article.

6

Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.

Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS. Jazirehi AR, et al. Cancer Res. 2011 Feb 15;71(4):1406-17. doi: 10.1158/0008-5472.CAN-10-1296. Epub 2010 Dec 15. Cancer Res. 2011. PMID: 21159666 Free PMC article. Retracted.

7

Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.

Jazirehi AR, Bonavida B. Jazirehi AR, et al. Methods Mol Biol. 2011;731:407-19. doi: 10.1007/978-1-61779-080-5_33. Methods Mol Biol. 2011. PMID: 21516425

8

Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review).

Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Bonavida B, et al. Int J Oncol. 1999 Oct;15(4):793-802. doi: 10.3892/ijo.15.4.793. Int J Oncol. 1999. PMID: 10493964 Review.

9

Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.

Jazirehi AR, Bonavida B. Jazirehi AR, et al. Mol Cancer Ther. 2004 Jan;3(1):71-84. Mol Cancer Ther. 2004. PMID: 14749477

10

CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

Onea AS, Jazirehi AR. Onea AS, et al. Among authors: jazirehi ar. Am J Cancer Res. 2016 Jan 15;6(2):403-24. eCollection 2016. Am J Cancer Res. 2016. PMID: 27186412 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page